Last 12 months
Inside the activity.
2 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 2 | 0 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 26, 2017 Filed May 30, 2017 16:55 UTC |
McVicar William K.President, R&D
|
GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001615219-17-000034 · wf-form4_149616330679650.xml · derivative · entry 1 McVicar William K. · CIK 0001634368 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2027-05-26 F1 · derivative.exercise_date: 25% of the total shares underlying this option vest on April 5, 2018 and the remaining shares vest 1/48 per month over the next 36 months thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 09:03 UTC |
Wessel ThomasChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0001615219-17-000010 · wf-form4_148492101344004.xml · derivative · entry 1 Wessel Thomas · CIK 0001456055 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2027-01-18 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from January 18, 2017. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 14:04 UTC |
Woo ElizabethSVP, Investor Relations
|
GrantStock Option (right to buy) · Derivative | 47,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0001615219-17-000011 · wf-form4_148492103170456.xml · derivative · entry 1 Woo Elizabeth · CIK 0001630686 · SVP, Investor Relations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires 2027-01-18 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from January 18, 2017. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 14:03 UTC |
McCabe John P.Chief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0001615219-17-000009 · wf-form4_148492099847637.xml · derivative · entry 1 McCabe John P. · CIK 0001630720 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2027-01-18 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from January 18, 2017. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 14:03 UTC |
Lindemann KatharineChief Operating Officer
|
GrantStock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0001615219-17-000008 · wf-form4_148492098003213.xml · derivative · entry 1 Lindemann Katharine · CIK 0001652493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2027-01-18 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from January 18, 2017. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 14:02 UTC |
Hadfield RobertGeneral Counsel & Secretary
|
GrantStock Option (right to buy) · Derivative | 57,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0001615219-17-000007 · wf-form4_148492096383173.xml · derivative · entry 1 Hadfield Robert · CIK 0001630687 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 57,000 shares Expires 2027-01-18 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from January 18, 2017. Read SEC document |
| November 08, 2016 Filed Nov 8, 2016 16:23 UTC |
Westphal Christoph HDirector · President and CEO · 10% owner
|
PurchaseCommon Stock | 7,000 | $7.31 | $51,170.00 |
DisclosureSEC source: 0001615219-16-000232 · wf-form4_147864022091781.xml · nonDerivative · entry 1 Westphal Christoph H · CIK 0001291961 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,941,118 F1 · price: The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $7.30 to $7.32. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
| November 07, 2016 Filed Nov 7, 2016 16:43 UTC |
Westphal Christoph HDirector · President and CEO · 10% owner
|
PurchaseCommon Stock | 8,870 | $5.70 | $50,559.00 |
DisclosureSEC source: 0001615219-16-000230 · wf-form4_147855499188160.xml · nonDerivative · entry 1 Westphal Christoph H · CIK 0001291961 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,934,118 F1 · price: The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $5.66 to $5.73. The reporting person will provide to the Issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
| November 07, 2016 Filed Nov 7, 2016 21:40 UTC |
McCabe John P.VP of Finance & Treasurer
|
PurchaseCommon Stock | 1,650 | $6.01 | $9,916.50 |
DisclosureSEC source: 0001615219-16-000228 · wf-form4_147855482137744.xml · nonDerivative · entry 1 McCabe John P. · CIK 0001630720 · VP of Finance & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 F1 · price: The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $5.99 to $6.01. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.